Enanta Pharmaceuticals’ (ENTA) Market Outperform Rating Reiterated at JMP Securities

JMP Securities reiterated their market outperform rating on shares of Enanta Pharmaceuticals (NASDAQ:ENTA) in a research note published on Tuesday,Benzinga reports. They currently have a $21.00 price objective on the biotechnology company’s stock, down from their prior price objective of $22.00.

Other analysts have also recently issued research reports about the stock. JPMorgan Chase & Co. lowered their target price on shares of Enanta Pharmaceuticals from $11.00 to $10.00 and set an “underweight” rating on the stock in a research note on Tuesday, August 6th. Evercore ISI upgraded Enanta Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, August 6th. Finally, HC Wainwright reissued a “buy” rating and issued a $27.00 target price on shares of Enanta Pharmaceuticals in a report on Thursday, October 10th. One research analyst has rated the stock with a sell rating, one has given a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Enanta Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $19.50.

Enanta Pharmaceuticals Price Performance

ENTA opened at $8.56 on Tuesday. The company has a market capitalization of $181.38 million, a P/E ratio of -1.57 and a beta of 0.56. The firm’s fifty day moving average price is $10.97 and its two-hundred day moving average price is $12.33. Enanta Pharmaceuticals has a fifty-two week low of $8.00 and a fifty-two week high of $17.80.

Institutional Trading of Enanta Pharmaceuticals

Several large investors have recently added to or reduced their stakes in ENTA. Allspring Global Investments Holdings LLC bought a new position in shares of Enanta Pharmaceuticals in the second quarter valued at approximately $35,000. US Bancorp DE raised its position in Enanta Pharmaceuticals by 4,933.7% in the 3rd quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 4,243 shares during the last quarter. State Board of Administration of Florida Retirement System acquired a new position in Enanta Pharmaceuticals in the first quarter worth $118,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Enanta Pharmaceuticals during the third quarter worth $122,000. Finally, Quest Partners LLC increased its stake in shares of Enanta Pharmaceuticals by 511.2% in the second quarter. Quest Partners LLC now owns 11,588 shares of the biotechnology company’s stock valued at $150,000 after buying an additional 9,692 shares in the last quarter. 94.99% of the stock is owned by institutional investors.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.